OGN Organon & Co.

NEUTRAL Impact: 2/10 DEFA14A
Horizon immediate Filed Apr 24, 2026 Processed 1mo ago SEC 0001193125-26-177445
Proxy solicitation materials
Latest settled — T+20d
OGN ▲ +1.94% at T+20d
NEUTRAL call ✓ call won +1.94% · α vs SPY -3.02% · entry $13.16 → $13.41
Next anchor: T+60d in 6w
Last close $13.39 (close Jun 8) · +1.79% from $13.16 entry
Entry anchored
Apr 24, 04:30 PM ET
via Databento tick
T+1d
+1.22%
call +1.22% · α +1.70%
$13.32
settled 6w ago
T+5d
+0.76%
call +0.76% · α +0.36%
$13.26
settled 6w ago
T+20d
+1.94%
call +1.94% · α -3.02%
$13.41
settled 19d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Organon & Co. filed a definitive proxy statement for its 2026 annual meeting, seeking shareholder approval for the election of 10 directors, executive compensation, an amendment to its stock plan, and the ratification of its auditor. The filing is routine and reflects standard corporate governance procedures.

Actionable Insight

This is a routine governance filing. Monitor the company's next 10-Q for any changes in financial guidance or operational updates.

Key Facts

  • The filing is a definitive proxy statement (DEFA14A) for Organon & Co.'s 2026 annual meeting.
  • Shareholders are asked to vote on four proposals: the election of 10 directors, approval of executive compensation, an amendment to the 2021 Incentive Stock Plan, and the ratification of PricewaterhouseCoopers as the independent auditor.
  • The board of directors recommends voting 'For' on all proposals.
  • The meeting will be held virtually on June 9, 2026.

Financial Impact

The filing does not contain new financial data or material changes to the company's financial structure.

Risk Factors

  • A shareholder vote against executive compensation (say on pay) could signal governance concerns, but the board's unanimous 'For' recommendation makes this unlikely.
  • Failure to ratify the auditor would be a significant negative event, but this is also highly improbable.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-177445
Document: 0001193125-26-177445-index-headers.html0001193125-26-177445
Document: 0001193125-26-177445-index.html0001193125-26-177445
Document: 0001193125-26-177445.txt0001193125-26-177445
10 reports for OGN
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+20▲ +1.94%Apr 27, 2026
Filters
Rows
Reports for OGN — sortable, filterable
Type Now
Jun 1, 2026
8d ago
PREM14A
BULLISH ★ 8/10
$13.37 $13.36▼ −0.04%▲ +2.71%$13.39 (+0.19%)
Apr 30, 2026
5w ago
DEFA14A
NEUTRAL ★ 3/10
$13.25 $13.31▲ +0.45%▼ −1.27%$13.39 (+1.09%)
Apr 30, 2026
5w ago
8-K
BEARISH ★ 6/10
$13.25 $13.31▼ −0.45%▲ +1.27%$13.39 (−1.09%)
Apr 27, 2026
6w ago
DEFA14A
BULLISH ★ 7/10
$13.32 $13.26▼ −0.41%▼ −2.10%$13.39 (+0.56%)
Apr 27, 2026
6w ago
DEFA14A
NEUTRAL ★ 5/10
$13.32 $13.26▼ −0.41%▼ −2.10%$13.39 (+0.56%)
Apr 27, 2026
6w ago
DEFA14A
BULLISH ★ 9/10
$13.16 $13.26▲ +0.76%▲ +0.36%$13.39 (+1.79%)
Apr 27, 2026
6w ago
DEFA14A
BULLISH ★ 8/10
$13.16 $13.26▲ +0.76%▲ +0.36%$13.39 (+1.79%)
Apr 27, 2026
6w ago
8-K
BULLISH ★ 8/10
$13.16 $13.26▲ +0.76%▲ +0.36%$13.39 (+1.79%)
Apr 24, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$13.16 $13.26▲ +0.76%▲ +0.36%$13.39 (+1.79%)
Mar 6, 2026
13w ago
Court Ruling
NEUTRAL ★ 4/10
$6.56 $6.34▼ −3.36%▼ −1.83%$13.39 (+104.27%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 7h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access